Tag Archives: Ventana Medical Systems

November 2016—Horizon Discovery has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as immunohistochemistry reference standards in cancer tissue diagnostics to support the development and validation of IHC assays.

July 2015—Halozyme Therapeutics and Ventana Medical Systems announced a global agreement to collaborate on the development of a companion diagnostic assay for use with Halozyme’s investigational new drug, PEGPH20, which Ventana would ultimately commercialize.

June 2015—Ventana Medical Systems has entered into a master collaboration agreement with Astellas Pharma, a research-and-development–driven pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.

November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.

November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.

August 2014—Ventana Medical Systems launched three robust prototype assays for the detection of biomarkers PSMA (prostate specific membrane antigen), MDM2 (mouse double minute 2), and FGFR (fibroblast growth factor receptor 2).

February 2014—Ventana Medical Systems received 510(k) clearance from the FDA for the Companion Algorithm ER (SP1) image-analysis algorithm used with the Ventana iScan Coreo scanner running Virtuoso software.

February 2014—Ventana Medical Systems’ HER2/neu (4B5) Rabbit Monoclonal Primary Antibody assay is a companion diagnostic for detecting HER2 protein expression in patients who, in countries where the drugs are approved, may be appropriate candidates for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine).

January 2014—Ventana Medical Systems announced the positive findings of the Primary ASC-US LSIL Marker Study (PALMS) that have been published in The Journal of the National Cancer Institute (Ikenberg H, et al. 2013;105[20]:1550–1557).

January 2014—Ventana Medical Systems launched the Ventana Gram Staining Kit. Automated for use on the Ventana BenchMark Special Stains instrument, the kit aids pathologists in the most basic classification of bacteria into gram-positive and gram-negative bacteria in fixed tissue samples.

December 2013—Ventana Medical Systems has entered into an agreement with Incyte to collaborate on the development of companion diagnostic tests for Incyte’s oncology drug programs, beginning with the Incyte IDO1 inhibitor program.

Ventana Medical Systems announced the global launch of its BRAF V600E immunohistochemistry test to detect the BRAF V600E mutation in a variety of tumors. The test, launched as a U.S. class I exempt/CE-IVD product, is designed to detect the most frequent BRAF mutation, V600E, which has been found to play a key role in a variety of cancers, including colorectal cancer.

Ventana Medical Systems and Boehringer Ingelheim have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.

Ventana Medical Systems has signed a worldwide agreement with health care imaging expert Barco to provide Barco’s diagnostic and clinical review display systems for use with Ventana’s Virtuoso image and workflow management system.